Why airlines shouldn't succumb to animal rights noise | Combo treatment shows promise against HIV in monkey study | Spider venom compound kills melanoma in mice, Tasmanian devil tumor cells
October 10, 2018
FBR Smartbrief
Top Stories
Why airlines shouldn't succumb to animal rights noise
Animal research is key to lifesaving medical breakthroughs and required by law before new treatments can be used to help humans, yet airlines are under pressure to erect barriers to this work by not transporting animals. Airlines that do so may very well be violating the law, in addition to complicating this critical research, writes Horace Cooper.
Townhall (10/10)
LinkedIn Twitter Facebook Google+ Email
Combo treatment shows promise against HIV in monkey study
A combination treatment targeted dormant HIV in immune cells, eliminating any trace of the virus in five of 11 monkeys after they were treated with antiretrovirals. Scientists say the treatment might have activated the latent virus, giving the antibody a target, but the researchers cautioned that the monkeys received antiretrovirals soon after being infected, potentially preventing a large viral reservoir.
Nature (free content) (10/3) 
LinkedIn Twitter Facebook Google+ Email
Research Breakthroughs
Spider venom compound kills melanoma in mice, Tasmanian devil tumor cells
Spider venom compound kills melanoma in mice, Tasmanian devil tumor cells
(Mark Ralston/AFP/Getty Images)
A compound in the venom of Australian funnel-web spiders has shown promise for killing melanoma cells and preventing the spread of cancer without harming healthy cells. The compound not only slowed melanoma progression in mice, but a modified version also quickly killed Tasmanian devil facial tumor cells, according to papers in Scientific Reports and Cell Death Discovery.
New Atlas (10/8) 
LinkedIn Twitter Facebook Google+ Email
Scientists validate tech for cancer detection in mice
New technology that uses three types of imaging for detection of solid cancers has been developed by researchers in Spain, and it delivered "excellent" imaging results in mice, researchers reported in ACS Applied Materials & Interfaces. No one type of imaging is optimal, according to researcher Marco Filice, but a blend of multiple types of imaging may allow detection of more cancers, potentially improving outcomes.
Radiology Business (10/5) 
LinkedIn Twitter Facebook Google+ Email
Prenatal gene editing tested in mice to treat congenital disease
Researchers from the University of Pennsylvania and the Children's Hospital of Philadelphia performed an early proof-of-concept procedure that involved a type of gene editing to eliminate a deadly liver disease known as hereditary tyrosinemia type 1 in the womb of mice. Details of the study were published in the journal Nature Medicine.
United Press International (10/8),  STAT (tiered subscription model) (10/8) 
LinkedIn Twitter Facebook Google+ Email
Other News
Animal Health
Mixture of helium, oxygen may improve equine surgical outcomes
Mixture of helium, oxygen may improve equine surgical outcomes
(Ian Forsyth/Getty Images)
A mixture of helium and oxygen delivered under high pressure resulted in lower peak inspiratory pressure and higher lung compliance than pure oxygen in anesthetized horses. The researchers plan to test a nitrogen-oxygen mixture as well and plan to study the heliox mixture in sheep, which closely model humans and could improve treatment for asthma and other respiratory conditions.
Gasworld (UK) (10/3) 
LinkedIn Twitter Facebook Google+ Email
Policy News
Lack of animal models among barriers to fighting hepatitis C
The development of an effective hepatitis C vaccine is important for reaching the goal of controlling the virus, but it faces significant obstacles, including a lack of animal models to determine whether experimental vaccines induce protective immunity, according to a report in Gastroenterology.
Healio (free registration)/HCVnext (10/5) 
LinkedIn Twitter Facebook Google+ Email
NCI awards $6.3M to Baylor medical school for prostate cancer research
Baylor College of Medicine was awarded $6.3 million from the National Cancer Institute through the Beau Biden Cancer Moonshot program for research on why prostate cancer tends to be more aggressive in African-American men and on the causes of racial disparities in prostate cancer mortality. Experts in molecular biology, animal research, and prostate cancer pathology and clinical management will collaborate at the Minority Patient-derived Xenograft Development and Trial Center to be established with the grant.
Health IT Analytics (10/5) 
LinkedIn Twitter Facebook Google+ Email
FBR News
Donate to FBR
For 35 years, FBR has advanced biomedical research for the sake of both human and animal health. We can't do our job without your support. Please give what you can. Together we will continue to make a difference.
LinkedIn Twitter Facebook Google+ Email
The more we do, the more we can do.
William Hazlitt,
LinkedIn Twitter Facebook Google+ Email
Learn more about FBR:
About FBR | Donate
About FBR
The Foundation for Biomedical Research (FBR) is the nation’s oldest and largest non-profit dedicated to improving human and animal health by promoting public understanding and support for biomedical research. Our mission is to educate people about the essential role animal research plays in the quest for medical advancements, treatments and cures for both people and animals.
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Editor  -  Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information